Cancer Biotherapy and Radiopharmaceuticals最新文献

{"title":"Research Progress of Cyclooxygenase-2 in Colorectal Adenomas.","authors":"Zhongsen Dou, Zhiwei Wang, Fanglai Zhu","doi":"10.1177/10849785261415777","DOIUrl":"10.1177/10849785261415777","url":null,"abstract":"<p><strong>Background: </strong>Cyclooxygenase-2 (COX-2) serves as a pivotal molecule bridging inflammation and tumor development, playing a central role in the initiation, progression, and malignant transformation of colorectal adenomas.</p><p><strong>Methods: </strong>This review systematically examines COX-2 expression patterns, molecular regulatory networks, and its potential applications in clinical diagnosis, prognosis assessment, and chemoprevention.</p><p><strong>Results: </strong>Evidence indicates that COX-2 exhibits significantly elevated expression in adenoma tissues (e.g., 54.8% positive rate in polyps vs. 18.5% in adjacent tissue), driving pathological progression through multiple mechanisms including cell proliferation induction, apoptosis inhibition, angiogenesis promotion, and tumor immune microenvironment remodeling. Nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors have demonstrated clear promise in adenoma chemoprevention (with agents such as celecoxib reducing advanced adenoma recurrence risk by 33%-45%).</p><p><strong>Conclusions: </strong>COX-2 is a critical early-event biomarker and therapeutic target in colorectal adenomas. Targeting the COX-2 pathway represents a viable strategy for prevention, although challenges regarding safety and personalized application remain.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"655-663"},"PeriodicalIF":1.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of Manual In-House Synthesis, Imaging, Biodistribution, and Dosimetry of Tb-161 PSMA-617 for mCRPC Patients in a Tertiary Health Care Center: A Proof-of-Concept Study.","authors":"Parul Thakral, Nishant Rana, Abhishek Uppal, Mrinalini Koley, Darshan Thakrani, Jatin Gupta, Vikas Kumar, Dharmender Malik, Ishita Sen","doi":"10.1177/10849785261454146","DOIUrl":"10.1177/10849785261454146","url":null,"abstract":"<p><strong>Background: </strong>Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge, particularly in patients with suboptimal response to ¹⁷⁷Lu-PSMA-617. Terbium-161 (Tb-161), with its emission of β-particles and high-LET Auger/conversion electrons, offers potential advantages in targeting micrometastases. However, clinical validation, especially in resource-limited settings, remains limited.</p><p><strong>Materials and methods: </strong>This single-center, proof-of-concept study was conducted at the Department of Nuclear Medicine, FMRI, Gurgaon. Manual in-house radiolabeling of PSMA-617 with Tb-161 was performed. The samples were withdrawn for quality control analyses. Five mCRPC patients were administered Tb-161 PSMA-617. Post-therapy planar and single-photon emission computed tomography/computed tomography (SPECT/CT) imaging was conducted to assess biodistribution and dosimetric analysis.</p><p><strong>Results: </strong>Radiolabeling PSMA-617 with Tb-161 was more than 95% efficient with 55 min of heating at 95°C. The radiochemical purity was >98% for all the runs (<i>n</i> = 5). The sample was found to be sterile with no gel formation seen after 15 d for all the batches. Post-therapy imaging demonstrated favorable biodistribution and high tumor uptake. Dosimetric analysis revealed absorbed doses comparable or superior to historical ¹⁷⁷Lu-PSMA-617 data. No acute adverse events or safety concerns were observed post administration.</p><p><strong>Conclusions: </strong>This study successfully demonstrates the feasibility of manual in-house synthesis and clinical application of Tb-161 PSMA-617 in an Indian tertiary care setting. The favorable synthesis, imaging, biodistribution, and dosimetric profile support its potential as a next-generation theranostic agent for mCRPC. These findings warrant further validation through larger, controlled clinical trials.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"721-732"},"PeriodicalIF":1.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148037871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On the Importance of Extracting the Needle from the Haystack.","authors":"Martin W Brechbiel, Alan G Harris, Craig H Sherman","doi":"10.1177/10849785261448799","DOIUrl":"10.1177/10849785261448799","url":null,"abstract":"","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"651-654"},"PeriodicalIF":1.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoformulations in Cancer: Focus on Patents and Clinical Trials.","authors":"Tahreen Taj, Joy Das, Utpal Bhui, Vijay Singh, Chowdhury Mobaswar Hossain, Anas Islam, Sathvik Belagodu Sridhar, Uttam Prasad Panigrahy, Priya Chaudhary, Sumel Ashique, Neeraj Mishra","doi":"10.1177/10849785261432081","DOIUrl":"10.1177/10849785261432081","url":null,"abstract":"<p><p>The transformation of a normal cell state to malignant cell is a multifactorial process, as cancer is a complex network of diseases. There are various types of cancer, each with its own underlying mechanisms and symptoms. The rise in modernization has significantly limited the mobility and has also altered the diets, leading to an increased rate of cancer mortality worldwide. The treatment options in cancer therapy, such as chemotherapy and radiotherapy, result in compromising the well-being of patients with cancer. Nanoformulation has emerged as an effective tool in cancer drug delivery. In order to gather pertinent information on Nanoformulations in Cancer Patents and Clinical Trials from the year 2000 to 2026, the majority of the electronic databases including Google Scholar, Embase, Web of Science, Scopus, and PubMed/MEDLINE were searched. The key benefits of nanoformulation lie in their ability to enhance the water solubility of drugs, thereby overcoming the limitations of traditional drug formulations. The nanoformulation facilitates efficiency and enhances therapeutic efficacy. The article also discusses the outcomes of the clinical trials that evaluated the effectiveness of the formulations. The current nanoformulation-based therapies can be a potential source to address the unmet medical needs that advance the patient outcomes.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"689-720"},"PeriodicalIF":1.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147576662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melatonin as an Epigenetic Modulator to Regulate Angiogenesis in Dalton's Lymphoma.","authors":"Anju Shrivastava, Rani Kumari","doi":"10.1177/10849785261430613","DOIUrl":"10.1177/10849785261430613","url":null,"abstract":"<p><strong>Background: </strong>Melatonin (<i>N</i>-acetyl-5-methoxy-tryptamine) is a promising antitumor agent and antioxidant. The pharmacological dose of melatonin has an oncostatic function by various means, including angiogenesis. Evidences indicate that melatonin, using multiple interrelated mechanisms, exhibits a variety of oncostatic properties in a variety of tumors during different stages of progression.</p><p><strong>Methodology: </strong>The present study was undertaken to investigate the epigenetic modulations in the vascular endothelial growth factor <i>VEGF, TIMP3</i>, and <i>CDH1</i> genes in Dalton lymphoma (DL) cells; furthermore, melatonin may reverse these epigenetic modulations. Endothelial cells (ECs) are the precursors for the development of new blood vessels; therefore, an EC proliferation assay was performed with and without DL ascites (DLA). EC migration leads to capillary formation, in which matrix metalloproteinases (<i>MMPs</i>) play a very important role in providing space for EC proliferation and migration. Furthermore, ECs were checked for <i>MMP-9</i> secretion through enzyme-linked immunosorbent assay. The <i>MMP</i> activity was also confirmed by gelatin zymography. Reactive oxygen species (ROS) level was also measured on ECs in the presence and absence of DLA. These activities of ECs or the tumor microenvironment were regulated by growth factors, such as <i>VEGF</i> secretion by cancer cells and the inhibition or silencing of endogenous antiangiogenic genes. In this, chromatin modification plays a very important role; also, in this, DNA methylation and histone deacetylases (<i>HDAC</i>s) play a significant role. So, in the DL cells, the authors try to find the <i>HDAC</i>s and <i>DNMT</i>s levels with respect to the control thymus cells by Reverse Transcription-polymerase chain reaction (RT-PCR). Further DNA methylation was checked by the MS-PCR technique. Proteins and melatonin were studied using VINA 2.0 software.</p><p><strong>Results: </strong>DLA promote a significant increase in EC proliferation and a high amount of <i>MMP-9</i> in the presence of DLA. The gelatin zymography also showed the high activity of <i>MMP-2</i> and <i>MMP-9</i> with respect to normal ECs. The ROS levels are also found to be high in DLA-induced ECs. The melatonin treatment successfully decreases EC proliferation, MMP-9 levels, and the <i>MMP-2</i> and <i>MMP-9</i> activities. The ROS levels were also reduced. The RT-PCR analysis showed that the melatonin modulates the alterations in <i>HDAC</i>1, 2, 6, and 9 and <i>DNMT1, DNMT3A</i> and <i>DNMT3B</i> with respect to the control. The MS-PCR results signify one of the possible ways of action of melatonin on DL cells.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"733-743"},"PeriodicalIF":1.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147482374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engrailed-1 Promotes Tumor Progression and Metastasis in Papillary Thyroid Cancer.","authors":"Liang Ning, Dong Chen, Zhongtao Zhang","doi":"10.1177/10849785261428404","DOIUrl":"10.1177/10849785261428404","url":null,"abstract":"<p><strong>Background and objective: </strong>Transcription factor Engrailed-1 (EN1) has been implicated as an oncogene in various solid tumors; however, its role in papillary thyroid carcinoma (PTC) is unknown. In the present study, the authors investigate the EN1 expression in PTC clinical specimens and its correlation with clinical outcomes, and then explore its function in PTC progression using <i>in vitro</i> and <i>in vivo</i> models.</p><p><strong>Methods: </strong>A retrospective cohort of 376 paired PTC was collected with informed consent. Immunohistochemistry for EN1 protein expression was evaluated. Clinic pathological data were recorded. EN1-specific shRNAs (or siRNAs) and overexpression plasmids were used. Using En-1 knockdown and overexpression, cell invasion, migration, proliferation, and apoptosis <i>in vitro</i> were detected using Transwell and wound healing assays, MTT, colony formation assay, and flow cytometry assay, respectively. Xenograft tumor models (subcutaneous) and tail-vein injection metastasis models (lung colonization) were established in mice.</p><p><strong>Results: </strong>EN1 is significantly overexpressed in PTC tissues; high EN1 expression is correlated with lymphovascular invasion (<i>p</i> < 0.05), lymph node metastasis (<i>p</i> < 0.05), TNM stage (<i>p</i> < 0.05), and recurrence (<i>p</i> < 0.05). Functionally enhanced EN1 expression promotes PTC cell invasion and migration, and promotes cell proliferation <i>in vitro</i>. Conversely, EN1 knockdown potently inhibited this invasive phenotype, induced significant apoptosis, and inhibited cell proliferation. EN1 silencing reduced tumor growth and lung metastatic potential in murine models <i>in vivo</i>. EN1 overexpression enhanced these malignant phenotypes <i>in vivo</i>.</p><p><strong>Conclusions: </strong>EN1 may be a novel driver of PTC aggressiveness and metastasis, suggesting its potential utility as a prognostic biomarker and therapeutic target.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"744-753"},"PeriodicalIF":1.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147437760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytochemicals in Oxidative Stress and Cancer Prevention: Emphasis on Seed-Derived Bioactives, Mechanistic Insights, and Nanotechnological Advances.","authors":"Areej, Hafiz Rizwan Sharif, Mian Kamran Sharif, Iahtisham-Ul-Haq, Abdur Rehman, Zafarullah Muhammad, Shoaib Younas, Ammar Al-Farga","doi":"10.1177/10849785261436375","DOIUrl":"10.1177/10849785261436375","url":null,"abstract":"<p><p>Phytochemicals are naturally occurring bioactive compounds found in plant seeds. These bioactive substances have attracted considerable attention for their proven potential to modulate oxidative stress and prevent cancer. Seeds are abundant in phenolics, flavonoids, terpenoids, chlorophylls, organosulfur compounds, and other important constituents, exhibited their potential as a strong antioxidant that can efficiently neutralize reactive oxygen species. By controlling lipid peroxidation and enhancing cellular resilience, antioxidants present in seeds maintain cellular redox balance, contribute to immunological modulation, and activate critical signaling pathways, including the Nrf2/Keap 1 and NF-κB signaling pathway, which governs the expression of proteins having antioxidant potential. Phytochemicals also exhibit strong anticancer properties by inducing apoptosis in cancerous cells while safeguarding healthy cells and tissues. The review emphasizes the potential of phytochemicals as selective growth inhibitors, endorsing their role as functional foods in various nutrition therapies. Beyond biological effects, nanotechnology has improved stability, solubility, and targeted delivery of phytochemicals, significantly enhanced their therapeutic potential. AI-driven approaches and omics technology has revolutionized the phytochemical discovery, formulation, and personalized applications. This review highlights the recent evidence from <i>in vitro</i>, <i>in vivo</i>, and clinical studies, alongside the translational relevance of phytochemicals in food and pharmaceutical industries. By merging molecular insights with technological advancements, this review explores the potential of phytochemicals in preventive and therapeutic strategies against chronic diseases. Future research should focus on personalized delivery systems, human efficacy, and harmonization to maximize their real-world impacts.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"664-688"},"PeriodicalIF":1.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147576669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic Suppression of Histone Deacetylase 4 Boosts T Cell Homing via CXCR3 in Lung Cancer: A Step Towards Ultrasound-Guided Immunotherapy.","authors":"Lingqiong Lan, Yi Wang, Liming Guo, Yongxin Xie","doi":"10.1177/10849785251403850","DOIUrl":"10.1177/10849785251403850","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is the biggest cause of cancer-correlated death worldwide, owing primarily to immune evasion and poor response to current immunotherapies.</p><p><strong>Objective: </strong>The aim of this work was focused on the immunomodulatory effect of histone deacetylase 4 (HDAC4) in tumor immunological milieu, specifically CD8⁺ T cell trafficking.</p><p><strong>Methods: </strong>Quantitative RT-PCR, immunofluorescence labeling, and FISH tests were used to determine HDAC4 and CXCR3 expression and location in lung cancer tissues. Flow cytometry assessed CD8⁺ T cell function, and histological analysis revealed tumor development.</p><p><strong>Results: </strong>Our results showed that HDAC4 was highly overexpressed in lung tumor samples, and it was associated with advanced clinical stage, lymph node metastases, and a worse overall survival rate. HDAC4 decreased CXCR3 expression, affecting CD8⁺ T cell infiltration and effector function. HDAC4 knockdown increased CD8⁺ T cell cytotoxicity, whereas CXCR3 inhibition reversed this effect. HDAC4 expression predicted poor survival with a ROC AUC of 0.78. SB939 treatment raised CXCR3 expression by 2.4 times and CD8⁺ infiltration by 39%.</p><p><strong>Conclusion: </strong>These findings point to HDAC4 as a crucial epigenetic regulator of immune cell trafficking in lung cancer. Given the growing interest in ultrasound-assisted medication delivery and immunological priming, our findings point to HDAC4 as a viable therapeutic target in ultrasound-guided immunomodulatory methods for lung cancer.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"574-582"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145859378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanobiological Ultrasound Simulation Reveals Suppression of Epithelial-to-Mesenchymal Transition and Stemness Programs in Colorectal Cancer.","authors":"Pei Nan Wen, Ming Shu Lin, Ji Cai Chen","doi":"10.1177/10849785261422983","DOIUrl":"10.1177/10849785261422983","url":null,"abstract":"<p><strong>Background: </strong>Dynamic characteristics such as cancer stemness and the epithelial-to-mesenchymal transition (EMT) cause the spread of colorectal cancer (CRC). Although there are now few pharmaceutical approaches, therapeutically correcting these conditions may improve prognosis. Acoustic radiation force and other mechanical ultrasonic forces have become new, noninvasive methods for modifying tumor biology. Nevertheless, little is known about their molecular influence on CRC EMT-stemness pathways.</p><p><strong>Materials and methods: </strong>The authors created a simulation pipeline to predict the effects of ultrasound-induced mechanical stress on CRC samples enriched for tumor-infiltrating T cells using transcriptome datasets (GSE108989). Heatmap visualizations, differential expression, pathway enrichment, principal component analysis (PCA), and EMT and stemness scores were computed using bulk RNA-seq. To evaluate mechanistic suppression, signaling axes such as TGF-β, Wnt/β-catenin, Notch, and yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) were investigated. The potential ultrasonic sensitivity of key gene modules was assessed.</p><p><strong>Results: </strong>Mesenchymal and stemness-associated transcriptional pathways were found to be downregulated in response to simulated acoustic modulation. Coherent clustering of decreased EMT/stemness genes was shown via heatmaps. Modified tumor groupings were identified by PCA. In the simulated postultrasound condition, canonical pathways associated with invasion, immunological evasion, and stemness maintenance were diminished. These results lend credence to the theory that CRC cellular plasticity may be reprogrammed by mechanical ultrasonic force.</p><p><strong>Conclusions: </strong>Early mechanistic understanding of how acoustic force-based ultrasound may inhibit EMT and stemness in CRC is provided by this transcriptome simulation. This data-driven approach presents ultrasound as a promising supplement to immune-oncology and antimetastatic methods and encourages more <i>in vitro</i> validation.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"636-643"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147312737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Efficacy of Capecitabine and Docetaxel Efficacy in Advanced Triple-Negative Breast Cancer Along with Ultrasound-Mediated Drug Delivery.","authors":"Dongbo Liu, Yujing Liu, Zhangyu Wang, Jian Chang, Guoqiang Zhang","doi":"10.1177/10849785261420926","DOIUrl":"10.1177/10849785261420926","url":null,"abstract":"<p><strong>Objective: </strong>To assess the clinical impact of docetaxel and capecitabine administered under ultrasound-mediated enhancement in patients with advanced triple-negative breast cancer (TNBC), with an emphasis on safety, quality of life, immunological modulation, and therapeutic efficacy.</p><p><strong>Methods: </strong>A total of 80 patients with advanced TNBC who received treatment at this institution between October 2021 and October 2022 were chosen at random and placed in either the control group (CG, <i>n</i> = 40) or the observation group (OG, <i>n</i> = 40). While the OG received capecitabine and docetaxel supplemented by an ultrasound-mediated drug delivery strategy intended to enhance intratumoral absorption, the CG received cisplatin and docetaxel. The groups were compared in terms of clinical response, immunological function, quality of life (FACT-B), incidence of adverse events, and serum tumor markers.</p><p><strong>Results: </strong>Compared with the CG, the OG showed a considerably greater response rate (RR) and disease control rate (<i>p</i> < 0.05). Immunoglobulin (Ig)G, IgM, and IgA levels in the CG dramatically decreased after two treatment cycles (<i>p</i> < 0.05), while levels in the OG were maintained and continued to be greater than those in the CG (<i>p</i> < 0.05). Both groups' FACT-B scores dropped (<i>p</i> < 0.05), but the OG's reduction was less noticeable (<i>p</i> < 0.05), suggesting that ultrasound-enhanced therapy improved quality-of-life preservation. The OG had decreased incidence of adverse events; however, this difference was not statistically significant (<i>p</i> > 0.05). Following therapy, tumor markers CA125 and CA153 reduced in both cohorts (<i>p</i> < 0.05), with the OG showing larger reductions (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Capecitabine and docetaxel administered via ultrasound improve therapeutic efficacy in advanced TNBC, lessen immune suppression brought on by treatment, improve quality of life, and support a positive safety profile while encouraging higher decreases in tumor marker expression. These results demonstrate the potential therapeutic benefit of using ultrasound-based medication delivery techniques into TNBC systemic therapy.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"559-564"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}